MLD on location at Plasmalogen Precursor formulation site

Dr. Shawn Ritchie and Dr. Tara Smith are currently in San Diego to visit the company that is handling all PPI-1040 formulation-related chemistry and final drug product manufacturing. The purpose of the visit is to tour the facility, review ongoing stability study protocols, and discuss future formulation advancements.

Coinciding with the visit is the arrival of the first large-scale batch of PPI-1040 from the drug manufacturer, which everyone at MLD is super excited about! This raw PPI-1040 active pharmaceutical ingredient will be formulated into final drug product in December, and then shipped to Montreal in January where it will be used as the test article in the first of several mandatory animal safety studies.

In it’s finished form, PPI-1040 is a fully stabilized and orally bioavailable plasmalogen precursor that is advantageous over ether-based precursors because it requires NO active metabolism by the body to convert it to an active plasmalogen. This is particularly relevant in cases of extreme plasmalogen deficiency as seen in RCDP, certain peroxisomal disorders, and adults with severe impairment.